These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9616911)

  • 21. [von Willebrand's disease].
    Mezzano D; Pereira J; Quiroga T
    Rev Med Chil; 1990 Mar; 118(3):320-9. PubMed ID: 2131515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder.
    Favaloro EJ
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):299-319. PubMed ID: 11686101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Von Willebrand disease: screening, diagnosis, and management.
    Totonchi A; Eshraghi Y; Beck D; McCrae K; Guyuron B
    Aesthet Surg J; 2008; 28(2):189-94. PubMed ID: 19083526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
    Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Molecular biology of von Willebrand disease].
    Melo-Nava B; Peñaloza R
    Rev Invest Clin; 2007; 59(5):401-8. PubMed ID: 18268896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Von Willebrand disease: a common and unrecognized bleeding disorder].
    Boehlen F; Robert-Ebadi H; de Moerloose P
    Rev Med Suisse; 2007 Feb; 3(97):346-50. PubMed ID: 17370733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology.
    Mazurier C; Goudemand J; Hilbert L; Caron C; Fressinaud E; Meyer D
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):337-47. PubMed ID: 11686103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. von Willebrand disease: from the bedside to therapy.
    Aledort LM
    Thromb Haemost; 1997 Jul; 78(1):562-5. PubMed ID: 9198216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis of von Willebrand disease subtypes: implications for treatment.
    Budde U
    Haemophilia; 2008 Nov; 14 Suppl 5():27-38. PubMed ID: 18786008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired von Willebrand syndrome: features and management.
    Mohri H
    Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease.
    Franchini M; Montagnana M; Lippi G
    Int J Lab Hematol; 2008 Apr; 30(2):91-4. PubMed ID: 18333841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. von Willebrand factor: biological function and molecular defects.
    Perutelli P; Biglino P; Mori PG
    Pediatr Hematol Oncol; 1997; 14(6):499-512. PubMed ID: 9383803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification.
    Budde U; Pieconka A; Will K; Schneppenheim R
    Semin Thromb Hemost; 2006 Jul; 32(5):514-21. PubMed ID: 16862525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of inherited von Willebrand disease in 2007.
    Federici AB; Mannucci PM
    Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function.
    Meyer D; Fressinaud E; Hilbert L; Ribba AS; Lavergne JM; Mazurier C
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):349-64. PubMed ID: 11686104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.